publication date: Apr. 20, 2018

CTEP Protocols

NCI Trials for April

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

 

Phase I – 10126

A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

City of Hope Comprehensive Cancer Center LAO

Herrera, Alex Francisco

(626) 256-4673 x 62405

 

Phase I – 10130

A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors and B-Cell Lymphomas with Hepatic Dysfunction

University Health Network Princess Margaret Cancer Center LAO

Renouf, Daniel John

(604) 877-6000

 

Phase I – 10131

A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Smyth, Lillian Mary

(646) 888-4894

 

Phase II – 10129

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

Yale University Cancer Center LAO

LoRusso, Patricia Mucci

(203) 785-5944

 

Phase II – EA2165

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

ECOG-ACRIN Cancer Research Group

Rajdev, Lakshmi

(718) 405-8404

 

Phase II – S1701

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

SWOG

Tsao, Anne S.

(713) 792-6363

 

Phase II – S1712

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

Yale University Cancer Center LAO

LoRusso, Patricia Mucci

(203) 785-5944

 

Phase II – 10129

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

SWOG

Sweet, Kendra

(813) 745-6841

 

Phase Other – AALL17B10-Q

DNA Methylation Stochasticity in Pediatric Acute Lymphoblastic Leukemia

Children’s Oncology Group

Koldobskiy, Michael A.

(410) 614-5055

 

Phase Other – AALL17B9-Q

The Genetics of Relapsed and Refractory T-Acute Lymphoblastic Leukemia (T-ALL)

Children’s Oncology Group

Ferrando, Adolfo A.

(212) 851-4611

Copyright (c) 2018 The Cancer Letter Inc.